Atherectomy Devices Market Updates

Atherectomy Devices Market size was valued at USD 962.41 Million in 2023 and is poised to grow from USD 1040.37 Million in 2024 to USD 1939.96 Million by 2032, growing at a CAGR of 8.1% during the forecast period (2025-2032).

Developing affordable and advanced atherectomy devices will be the prime focus of new as well as established companies in the future. Atherectomy devices providers can also maximize their business scope by riding the wave of minimally invasive surgery popularity going forward. Investing in research and development will be an unmissable strategy for all atherectomy devices companies working in this market. Emerging countries will provide attractive growth opportunities for atherectomy devices suppliers in the long run. 'Medtronic Plc (Ireland) ', 'Boston Scientific Corporation (USA) ', 'Cardiovascular Systems, Inc. (USA) ', 'Royal Philips (Netherlands) ', 'Avinger, Inc. (USA) ', 'Terumo Corporation (Japan) ', 'AngioDynamics, Inc. (USA) ', 'Braun Group (Germany) ', 'Abbott Laboratories (USA) ', 'B. Braun Melsungen AG (Germany) ', 'Biotronik SE & Co. KG (Germany) ', 'Biomerics (USA) ', 'Philips (Netherlands) ', 'Cook Medical, Inc. (USA) ', 'Cardinal Health, Inc. (USA) ', 'Rex Medical, L.P. (USA) ', 'W. L. Gore & Associates, Inc. (USA) ', 'Minnetronix, Inc. (USA) ', 'Merit Medical Systems, Inc. (USA) ', 'NexStep Medical (USA)'

An aging population is more at risk of suffering from cardiovascular complications such as arterial blockages. Atherectomy devices are crucial in helping treat these disorders and growing preference for minimally invasive atherectomy procedures among geriatric people will also bolster atherectomy devices market growth in the future.

Integration of Advanced Technologies: Atherectomy device manufacturers should focus on integrating advanced technologies such as artificial intelligence and machine learning to improve the capabilities of their offerings. Companies can deploy these advanced technologies in their development as well as deployment to maximize business scope in the future.

North America is projected to account for a dominant share of the global atherectomy devices market. High incidence of multiple cardiovascular disorders and growing number of atherectomy procedures in this region allow it to hold a dominant stance. Rapidly increasing geriatric population, rising popularity of minimally invasive surgeries, and approvals of novel atherectomy devices are also expected to contribute to this region's dominance. The United States is projected to spearhead sales of atherectomy devices in the North American region followed by Canada. High healthcare expenditure in this region will also favor atherectomy device sales.